The role of vascular endothelial growth factor A polymorphisms in breast cancer

International Journal of Molecular Sciences

Volumn 13, Issue 11, 2012, Pages 14845-14864

  Sa nguanraksa, Doonyapat ^a   O charoenrat, Pornchai ^a  

^a MAHIDOL UNIVERSITY   (Thailand)

Author keywords

Angiogenesis; Breast cancer; Polymorphism; Vascular endothelial growth factor

Indexed keywords

BEVACIZUMAB; CAPECITABINE; DOCETAXEL; NAVELBINE; PACLITAXEL; PLACEBO; VASCULOTROPIN A; VASCULOTROPIN;

5' UNTRANSLATED REGION; ADVANCED CANCER; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PROGNOSIS; CANCER RISK; CANCER SURVIVAL; DNA SEQUENCE; DRUG EFFICACY; GENE FUNCTION; GENE MUTATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENETIC RISK; GENETIC TRANSCRIPTION; GENETIC VARIABILITY; HUMAN; LYMPHANGIOGENESIS; METASTASIS; ONCOGENE; OVERALL SURVIVAL; PROTEIN BLOOD LEVEL; PROTEIN FUNCTION; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; TUMOR VASCULARIZATION; VASCULAR ENDOTHELIAL GROWTH FACTOR A GENE; ANIMAL; BREAST NEOPLASMS; DISEASE COURSE; DRUG EFFECTS; FEMALE; GENE EXPRESSION REGULATION; GENETIC PREDISPOSITION; GENETICS; METABOLISM; MOLECULARLY TARGETED THERAPY; NEOVASCULARIZATION (PATHOLOGY); PATHOLOGY; RISK;

ANIMALS; BREAST NEOPLASMS; DISEASE PROGRESSION; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; GENETIC PREDISPOSITION TO DISEASE; HUMANS; MOLECULAR TARGETED THERAPY; NEOVASCULARIZATION, PATHOLOGIC; POLYMORPHISM, GENETIC; POLYMORPHISM, SINGLE NUCLEOTIDE; RISK; VASCULAR ENDOTHELIAL GROWTH FACTOR A; VASCULAR ENDOTHELIAL GROWTH FACTORS;

EID: 84870704754     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms131114845     Document Type: Review

References (95)

1. Jemal, A.; Bray, F.; Center, M.M.; Ferlay, J.; Ward, E.; Forman, D. Global cancer statistics. CA Cancer J. Clin. 2011, 61, 69-90.
2. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: the next generation. Cell 2011, 144, 646-674.
3. Bergers, G.; Benjamin, L.E. Tumorigenesis and the angiogenic switch. Nat. Rev. 2003, 3, 401-410.
4. Jain, R.K. Determinants of tumor blood flow: A review. Cancer Res. 1988, 48, 2641-2658.
5. Jain, R.K.; Munn, L.L.; Fukumura, D. Dissecting tumour pathophysiology using intravital microscopy. Nat. Rev. 2002, 2, 266-276.
6. Anderson, S.A.; Glod, J.; Arbab, A.S.; Noel, M.; Ashari, P.; Fine, H.A.; Frank, J.A. Noninvasive MR imaging of magnetically labeled stem cells to directly identify neovasculature in a glioma model. Blood 2005, 105, 420-425.
7. Djonov, V.; Andres, A.-C.; Ziemiecki, A. Vascular remodelling during the normal and malignant life cycle of the mammary gland. Microsc. Res. Tech. 2001, 52, 182-189.
8. Brem, S.S.; Gullino, P.M.; Medina, D. Angiogenesis: A marker for neoplastic transformation of mammary papillary hyperplasia. Science 1977, 195, 880-882.
9. Jensen, H.M.; Chen, I.; DeVault, M.R.; Lewis, A.E. Angiogenesis induced by "normal" human breast tissue: a probable marker for precancer. Science 1982, 218, 293-295.
10. Guinebretiere, J.M.; le Monique, G.; Gavoille, A.; Bahi, J.; Contesso, G. Angiogenesis and risk of breast cancer in women with fibrocystic disease. J. Natl. Cancer Inst. 1994, 86, 635-636.
11. Weidner, N.; Folkman, J.; Pozza, F.; Bevilacqua, P.; Allred, E.N.; Moore, D.H.; Meli, S.; Gasparini, G. Tumor angiogenesis: A new significant and independent prognostic indicator in early-stage breast carcinoma. J. Natl. Cancer Inst. 1992, 84, 1875-1887.
12. Weidner, N.; Semple, J.P.; Welch, W.R.; Folkman, J. Tumor angiogenesis and metastasis-correlation in invasive breast carcinoma. N. Engl. J. Med. 1991, 324, 1-8.
13. Uzzan, B.; Nicolas, P.; Cucherat, M.; Perret, G.Y. Microvessel density as a prognostic factor in women with breast cancer: a systematic review of the literature and meta-analysis. Cancer Res. 2004, 64, 2941-2955.
14. Vincenti, V.; Cassano, C.; Rocchi, M.; Persico, G. Assignment of the vascular endothelial growth factor gene to human chromosome 6p21.3. Circulation 1996, 93, 1493-1495.
15. Houck, K.A. The vascular endothelial growth factor family: Identification of a fourth molecular species and characterization of alternative splicing of RNA. Mol. Endocrinol. 1991, 5, 1806-1814.
16. Tischer, E. The human gene for vascular endothelial growth factor. Multiple protein forms are encoded through alternative exon splicing. J. Biol. Chem. 1991, 266, 11947-11954.
17. Neufeld, G.; Cohen, T.; Gengrinovitch, S.; Poltorak, Z. Vascular endothelial growth factor (VEGF) and its receptors. FASEB J. 1999, 13, 9-22.
18. Leung, D.W.; Cachianes, G.; Kuang, W.J.; Goeddel, D.V.; Ferrara, N. Vascular endothelial growth factor is a secreted angiogenic mitogen. Science 1989, 246, 1306-1309.
19. Plouet, J.; Schilling, J.; Gospodarowicz, D. Isolation and characterization of a newly identified endothelial cell mitogen produced by AtT20 cells. EMBO J. 1989, 8, 3801-3808.
20. Nagy, J.A. Vascular permeability factor/vascular endothelial growth factor induces lymphangiogenesis as well as angiogenesis. J. Exp. Med. 2002, 196, 1497-1506.
21. Matsumoto, T.; Claesson-Welsh, L. VEGF receptor signal transduction. Science STKE 2001, 112, 1-17.
22. Gerber, H.P. VEGF regulates endothelial cell survival by the PI3-kinase/Akt signal transduction pathway. Requirement for Flk-1/KDR activation. J. Biol. Chem. 1998, 273, 30366-30343.
23. Gerber, H.P.; Dixit, V.; Ferrara, N. Vascular endothelial growth factor induces expression of the antiapoptotic proteins Bcl-2 and A1 in vascular endothelial cells. J. Biol. Chem. 1998, 273, 13313-13316.
24. Gerber, H.P. VEGF is required for growth and survival in neonatal mice. Development 1999, 126, 1149-1159.
25. Benjamin, L.E.; Golijanin, D.; Itin, A.; Pode, D.; Keshet, E. Selective ablation of immature blood vessels in established human tumors follows vascular endothelial growth factor withdrawal. J. Clin. Invest. 1999, 103, 159-165.
26. Yuan, F. Time-dependent vascular regression and permeability changes in established human tumor xenografts induced by an anti-vascular endothelial growth factor/vascular permeability factor antibody. Proc. Natl. Acad. Sci. USA 1996, 93, 14765-14770.
27. Senger, D.R. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983, 219, 983-985.
28. Dvorak, H.F.; Brown, L.F.; Detmar, M.; Dvorak, A.M. Vascular permeability factor/vascular endothelial growth factor, microvascular hyperpermeability, and angiogenesis. Am. J. Pathol. 1995, 146, 1029-1039.
29. Bates, D.O.; Curry, F.E. Vascular endothelial growth factor increases microvascular permeability via a Ca(2+)-dependent pathway. Am. J. Physiol. 1997, 273, H687-H694.
30. Roberts, W.G.; Palade, G.E. Increased microvascular permeability and endothelial fenestration induced by vascular endothelial growth factor. J. Cell. Sci. 1995, 108, 2369-2379.
31. Ku, D.D.; Zaleski, J.K.; Liu, S.; Brock, T.A. Vascular endothelial growth factor induces EDRF-dependent relaxation in coronary arteries. Am. J. Physiol. 1993, 265, H586-H592.
32. Yang, R. Effects of vascular endothelial growth factor on hemodynamics and cardiac performance. J. Cardiovasc. Pharmacol. 1996, 27, 838-844.
33. Kim, K.J. Inhibition of vascular endothelial growth factor-induced angiogenesis suppresses tumor growth in vivo. Nature 1993, 362, 841-844.
34. Ferrara, N.; Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18, 4-25.
35. Fukumura, D. Tumor induction of VEGF promoter activity in stromal cells. Cell 1998, 94, 715-725.
36. Gerber, H.P.; Kowalski, J.; Sherman, D.; Eberhard, D.A.; Ferrara, N. Complete inhibition of rhabdomyosarcoma xenograft growth and neovascularization requires blockade of both tumor and host vascular endothelial growth factor. Cancer Res. 2000, 60, 6253-6258.
37. Tsuzuki, Y. Vascular endothelial growth factor (VEGF) modulation by targeting hypoxia-inducible factor-1[alpha→hypoxia response element→VEGF cascade differ entially regulates vascular response and growth rate in tumors. Cancer Res. 2000, 60, 6248-6252.
38. Bergers, G. Matrix metalloproteinase-9 triggers the angiogenic switch during carcinogenesis. Nat. Cell. Biol. 2000, 2, 737-744.
39. Gasparini, G. Prognostic value of vascular endothelial growth factor in breast cancer. Oncologist 2000, 5, 37-44.
40. Salven, P.; Perhoniemi, V.; Tykka, H.; Maenpaa, H.; Joensuu, H. Serum VEGF levels in women with a benign breast tumor or breast cancer. Breast Cancer Res. Treat. 1999, 53, 161-166.
41. Obermair, A.; Kucera, E.; Mayerhofer, K.; Speiser, P.; Seifert, M.; Czerwenka, K.; Kaider, A.; Leodolter, S.; Kainz, C.; Zeillinger, R. Vascular endothelial growth factor (VEGF) in human breast cancer: correlation with disease-free survival. Int. J. Cancer 1997, 74, 455-458.
42. Ghosh, S.; Sullivan, C.A.; Zerkowski, M.P.; Molinaro, A.M.; Rimm, D.L.; Camp, R.L.; Chung, G.G. High levels of vascular endothelial growth factor and its receptors (VEGFR-1, VEGFR-2, neuropilin-1) are associated with worse outcome in breast cancer. Human Pathol. 2008, 39, 1835-1843.
43. Xie, X.D.; Qu, S.X.; Liu, Z.Z.; Zhang, F.; Zheng, Z.D. Study on relationship between angiogenesis and micrometastases of peripheral blood in breast cancer. J. Cancer Res. Clin. 2009, 135, 413-419.
44. Manders, P.; Beex, L.V.; Tjan-Heijnen, V.C.; Geurts-Moespot, J.; van Tienoven, T.H.; Foekens, J.A.; Sweep, C.G. The prognostic value of vascular endothelial growth factor in 574 node-negative breast cancer patients who did not receive adjuvant systemic therapy. Br. J. Cancer 2002, 87, 772-778.
45. Bando, H.; Weich, H.A.; Brokelmann, M.; Horiguchi, S.; Funata, N.; Ogawa, T.; Toi, M. Association between intratumoral free and total VEGF, soluble VEGFR-1, VEGFR-2 and prognosis in breast cancer. Br. J. Cancer 2005, 92, 553-561.
46. Toi, M.; Bando, H.; Ogawa, T.; Muta, M.; Hornig, C.; Weich, H.A. Significance of vascular endothelial growth factor (VEGF)/soluble VEGF receptor-1 relationship in breast cancer. Int. J. Cancer 2002, 98, 14-18.
47. Ryden, L.; Stendahl, M.; Jonsson, H.; Emdin, S.; Bengtsson, N.O.; Landberg, G. Tumor-specific VEGF-A and VEGFR2 in postmenopausal breast cancer patients with long-term follow-up. Implication of a link between VEGF pathway and tamoxifen response. Breast Cancer Res. Treat. 2005, 89, 135-143.
48. Burstein, H.J.; Chen, Y.H.; Parker, L.M.; Savoie, J.; Younger, J.; Kuter, I.; Ryan, P.D.; Garber, J.E.; Chen, H.; Campos, S.M.; et al. VEGF as a marker for outcome among advanced breast cancer patients receiving anti-VEGF therapy with bevacizumab and vinorelbine chemotherapy. Clin. Cancer Res. 2008, 14, 7871-7877.
49. Brogan, I.J.; Khan, N.; Isaac, K.; Hutchinson, J.A.; Pravica, V.; Hutchinson, I.V. Novel polymorphisms in the promoter and 5' UTR regions of the human vascular endothelial growth factor gene. Hum. Immunol. 1999, 60, 1245-1249.
50. Watson, C.J.; Webb, N.J.; Bottomley, M.J.; Brenchley, P.E. Identification of polymorphisms within the vascular endothelial growth factor (VEGF) gene: Correlation with variation in VEGF protein production. Cytokine 2000, 12, 1232-1235.
51. Jin, Q.; Hemminki, K.; Enquist, K.; Lenner, P.; Grzybowska, E.; Klaes, R.; Henriksson, R.; Chen, B.; Pamula, J.; Pekala, W.; et al. Vascular endothelial growth factor polymorphisms in relation to breast cancer development and prognosis. Clin. Cancer Res. 2005, 11, 3647-3653.
52. Awata, T.; Inoue, K.; Kurihara, S.; Ohkubo, T.; Watanabe, M.; Inukai, K.; Inoue, I.; Katayama, S. A common polymorphism in the 5'-untranslated region of the VEGF gene is associated with diabetic retinopathy in type 2 diabetes. Diabetes 2002, 51, 1635-1639.
53. Shahbazi, M.; Fryer, A.A.; Pravica, V.; Brogan, I.J.; Ramsay, H.M.; Hutchinson, I.V.; Harden, P.N. Vascular endothelial growth factor gene polymorphisms are associated with acute renal allograft rejection. J. Am. Soc. Nephrol. 2002, 13, 260-264.
54. Koukourakis, M.I.; Papazoglou, D.; Giatromanolaki, A.; Bougioukas, G.; Maltezos, E.; Sivridis, E. VEGF gene sequence variation defines VEGF gene expression status and angiogenic activity in non-small cell lung cancer. Lung Cancer 2004, 46, 293-298.
55. Stevens, A.; Soden, J.; Brenchley, P.E.; Ralph, S.; Ray, D.W. Haplotype analysis of the polymorphic human vascular endothelial growth factor gene promoter. Cancer Res. 2003, 63, 812-816.
56. Pages, G.; Pouyssegur, J. Transcriptional regulation of the Vascular Endothelial Growth Factor gene-a concert of activating factors. Cardiovasc. Res. 2005, 65, 564-573.
57. Morris, J.F.; Hromas, R.; Rauscher, F.J., III. Characterization of the DNA-binding properties of the myeloid zinc finger protein MZF1: two independent DNA-binding domains recognize two DNA consensus sequences with a common G-rich core. Mol. Cell. Biol. 1994, 14, 1786-1795.
58. Awata, T.; Kurihara, S.; Takata, N.; Neda, T.; Iizuka, H.; Ohkubo, T.; Osaki, M.; Watanabe, M.; Nakashima, Y.; Inukai, K.; et al. Functional VEGF C-634G polymorphism is associated with development of diabetic macular edema and correlated with macular retinal thickness in type 2 diabetes. Biochem. Biophys. Res. Commun. 2005, 333, 679-685.
59. Huez, I.; Bornes, S.; Bresson, D.; Creancier, L.; Prats, H. New vascular endothelial growth factor isoform generated by internal ribosome entry site-driven CUG translation initiation. Mol. Endocrinol. 2001, 15, 2197-2210.
60. Krippl, P.; Langsenlehner, U.; Renner, W.; Yazdani-Biuki, B.; Wolf, G.; Wascher, T.C.; Paulweber, B.; Haas, J.; Samonigg, H. A common 936 C/T gene polymorphism of vascular endothelial growth factor is associated with decreased breast cancer risk. Int. J. Cancer 2003, 106, 468-471.
61. Renner, W.; Kotschan, S.; Hoffmann, C.; Obermayer-Pietsch, B.; Pilger, E. A common 936 C/T mutation in the gene for vascular endothelial growth factor is associated with vascular endothelial growth factor plasma levels. J. Vasc. Res. 2000, 37, 443-448.
62. Doi, K.; Noiri, E.; Nakao, A.; Fujita, T.; Kobayashi, S.; Tokunaga, K. Functional polymorphisms in the vascular endothelial growth factor gene are associated with development of end-stage renal disease in males. J. Am. Soc. Nephrol. 2006, 17, 823-830.
63. Abe, A.; Sato, K.; Habuchi, T.; Wang, L.; Li, Z.; Tsuchiya, N.; Ohyama, C.; Satoh, S.; Ogawa, O.; Kato, T. Single nucleotide polymorphisms in the 3' untranslated region of vascular endothelial growth factor gene in Japanese population with or without renal cell carcinoma. Tohoku J. Exp. Med. 2002, 198, 181-190.
64. Garcia-Closas, M.; Malats, N.; Real, F.X.; Yeager, M.; Welch, R.; Silverman, D.; Kogevinas, M.; Dosemeci, M.; Figueroa, J.; Chatterjee, N.; et al. Large-scale evaluation of candidate genes identifies associations between VEGF polymorphisms and bladder cancer risk. PLoS Genet. 2007, 3, e29.
65. Jacobs, E.J.; Feigelson, H.S.; Bain, E.B.; Brady, K.A.; Rodriguez, C.; Stevens, V.L.; Patel, A.V.; Thun, M.J.; Calle, E.E. Polymorphisms in the vascular endothelial growth factor gene and breast cancer in the Cancer Prevention Study II cohort. Breast Cancer Res. 2006, 8, R22.
66. Schneider, B.P.; Radovich, M.; Sledge, G.W.; Robarge, J.D.; Li, L.; Storniolo, A.M.; Lemler, S.; Nguyen, A.T.; Hancock, B.A.; Stout, M.; et al. Association of polymorphisms of angiogenesis genes with breast cancer. Breast Cancer Res. Treat. 2008, 111, 157-163.
67. Kidd, L.R.; Brock, G.N.; VanCleave, T.T.; Benford, M.L.; Lavender, N.A.; Kruer, T.L.; Wittliff, J.L. Angiogenesis-associated sequence variants relative to breast cancer recurrence and survival. Cancer Causes Control 2010, 21, 1545-1557.
68. Langsenlehner, U.; Wolf, G.; Langsenlehner, T.; Gerger, A.; Hofmann, G.; Clar, H.; Wascher, T.C.; Paulweber, B.; Samonigg, H.; Krippl, P.; et al. Genetic polymorphisms in the vascular endothelial growth factor gene and breast cancer risk. The Austrian "tumor of breast tissue: incidence, genetics, and environmental risk factors" study. Breast Cancer Res. Treat. 2008, 109, 297-304.
69. Balasubramanian, S.P.; Cox, A.; Cross, S.S.; Higham, S.E.; Brown, N.J.; Reed, M.W. Influence of VEGF-A gene variation and protein levels in breast cancer susceptibility and severity. Int. J. Cancer 2007, 121, 1009-1016.
70. Kataoka, N.; Cai, Q.; Wen, W.; Shu, X.O.; Jin, F.; Gao, Y.T.; Zheng, W. Population-based case-control study of VEGF gene polymorphisms and breast cancer risk among Chinese women. Cancer Epidemiol. Biomark. Prev. 2006, 15, 1148-1152.
71. Smith, K.C.; Bateman, A.C.; Fussell, H.M.; Howell, W.M. Cytokine gene polymorphisms and breast cancer susceptibility and prognosis. Eur. J. Immunogenet. 2004, 31, 167-173.
72. Oliveira, C.; Lourenco, G.J.; Silva, P.M.; Cardoso-Filho, C.; Favarelli, M.H.; Goncales, N.S.; Gurgel, M.S.; Lima, C.S. Polymorphisms in the 5'-and 3'-untranslated region of the VEGF gene and sporadic breast cancer risk and clinicopathologic characteristics. Tumour Biol. 2011, 32, 295-300.
73. Beeghly-Fadiel, A.; Shu, X.O.; Lu, W.; Long, J.; Cai, Q.; Xiang, Y.B.; Zheng, Y.; Zhao, Z.; Gu, K.; Gao, Y.T.; et al. Genetic variation in VEGF family genes and breast cancer risk: A report from the Shanghai Breast Cancer Genetics Study. Cancer Epidemiol. Biomark. Prev. 2011, 20, 33-41.
74. Eroglu, A.; Ozturk, A.; Cam, R.; Akar, N. Vascular endothelial growth factor gene 936 C/T polymorphism in breast cancer patients. Med. Oncol. 2008, 25, 54-55.
75. Gerger, A.; Langsenlehner, U.; Renner, W.; Weitzer, W.; Eder, T.; Yazdani-Biuki, B.; Hofmann, G.; Samonigg, H.; Krippl, P. A multigenic approach to predict breast cancer risk. Breast Cancer Res. Treat. 2007, 104, 159-164.
76. Jakubowska, A.; Gronwald, J.; Menkiszak, J.; Gorski, B.; Huzarski, T.; Byrski, T.; Edler, L.; Lubinski, J.; Scott, R.J.; Hamann, U. The VEGF_936_C>T 3'UTR polymorphism reduces BRCA1-associated breast cancer risk in Polish women. Cancer Lett. 2008, 262, 71-76.
77. Jakubowska, A.; Jaworska, K.; Cybulski, C.; Janicka, A.; Szymanska-Pasternak, J.; Lener, M.; Narod, S.A.; Lubinski, J. Do BRCA1 modifiers also affect the risk of breast cancer in non-carriers? Eur. J. Cancer 2009, 45, 837-842.
78. Rodrigues, P.; Furriol, J.; Tormo, E.; Ballester, S.; Lluch, A.; Eroles, P. The single-nucleotide polymorphisms +936 C/T VEGF and-710 C/T VEGFR1 are associated with breast cancer protection in a Spanish population. Breast Cancer Res. Treat. 2012, 133, 769-778.
79. Zhang, B.; Beeghly-Fadiel, A.; Lu, W.; Cai, Q.; Xiang, Y.B.; Zheng, Y.; Long, J.; Ye, C.; Gu, K.; Shu, X.O.; et al. Evaluation of functional genetic variants for breast cancer risk: results from the Shanghai breast cancer study. Am. J. Epidemiol. 2011, 173, 1159-1170.
80. Etienne-Grimaldi, M.C.; Formento, P.; Degeorges, A.; Pierga, J.Y.; Delva, R.; Pivot, X.; Dalenc, F.; Espie, M.; Veyret, C.; Formento, J.L.; et al. Prospective analysis of the impact of VEGF-A gene polymorphisms on the pharmacodynamics of bevacizumab-based therapy in metastatic breast cancer patients. Br. J. Clin. Pharmacol. 2011, 71, 921-928.
81. Lu, H.; Shu, X.O.; Cui, Y.; Kataoka, N.; Wen, W.; Cai, Q.; Ruan, Z.X.; Gao, Y.T.; Zheng, W. Association of genetic polymorphisms in the VEGF gene with breast cancer survival. Cancer Res. 2005, 65, 5015-5019.
82. Wolf, G.; Aigner, R.M.; Schaffler, G.; Langsenlehner, U.; Renner, W.; Samonigg, H.; Yazdani-Biuki, B.; Krippl, P. The 936C>T polymorphism of the gene for vascular endothelial growth factor is associated with 18F-fluorodeoxyglucose uptake. Breast Cancer Res. Treat. 2004, 88, 205-208.
83. Knechtel, G.; Hofmann, G.; Gerger, A.; Renner, W.; Langsenlehner, T.; Szkandera, J.; Wolf, G.; Samonigg, H.; Krippl, P.; Langsenlehner, U. Analysis of common germline polymorphisms as prognostic factors in patients with lymph node-positive breast cancer. J. Cancer Res. Clin. 2010, 136, 1813-1819.
84. Wang, K.; Liu, L.; Zhu, Z.M.; Shao, J.H.; Xin, L. Five polymorphisms of vascular endothelial growth factor (VEGF) and risk of breast cancer: a meta-analysis involving 16,703 individuals. Cytokine 2011, 56, 167-173.
85. Yang, D.S.; Park, K.H.; Woo, O.H.; Woo, S.U.; Kim, A.R.; Lee, E.S.; Lee, J.B.; Kim, Y.H.; Kim, J.S.; Seo, J.H. Association of a vascular endothelial growth factor gene 936 C/T polymorphism with breast cancer risk: a meta-analysis. Breast Cancer Res. Treat. 2011, 125, 849-853.
86. Gu, D.; Wang, M. VEGF 936C>T polymorphism and breast cancer risk: evidence from 5729 cases and 5868 controls. Breast Cancer Res. Treat. 2011, 125, 489-493.
87. Liu, L.; Liu, L.; Zeng, F.; Wang, K.; Huang, J.; Xin, L.; Zhu, P.Q. Meta-analysis of the association between VEGF-634 G>C and risk of malignancy based on 23 case-control studies. J. Cancer Res. Clin. 2011, 137, 1027-1036.
88. Miller, K.; Wang, M.; Gralow, J.; Dickler, M.; Cobleigh, M.; Perez, E.A.; Shenkier, T.; Cella, D.; Davidson, N.E. Paclitaxel plus bevacizumab versus paclitaxel alone for metastatic breast cancer. N. Engl. J. Med. 2007, 357, 2666-2676.
89. Miles, D.W.; Chan, A.; Dirix, L.Y.; Cortes, J.; Pivot, X.; Tomczak, P.; Delozier, T.; Sohn, J.H.; Provencher, L.; Puglisi, F.; et al. Phase III study of bevacizumab plus docetaxel compared with placebo plus docetaxel for the first-line treatment of human epidermal growth factor receptor 2-negative metastatic breast cancer. J. Clin. Oncol. 2010, 28, 3239-3247.
90. Thomssen, C.; Pierga, J.Y.; Pritchard, K.I.; Biganzoli, L.; Cortes-Funes, H.; Petrakova, K.; Kaufman, B.; Duenne, A.; Smith, I. First-line bevacizumab-containing therapy for triple-negative breast cancer: analysis of 585 patients treated in the ATHENA study. Oncology 2012, 82, 218-227.
91. Miller, K.D.; Chap, L.I.; Holmes, F.A.; Cobleigh, M.A.; Marcom, P.K.; Fehrenbacher, L.; Dickler, M.; Overmoyer, B.A.; Reimann, J.D.; et al. Randomized phase III trial of capecitabine compared with bevacizumab plus capecitabine in patients with previously treated metastatic breast cancer. J. Clin. Oncol. 2005, 23, 792-799.
92. Kostopoulos, I.; Arapantoni-Dadioti, P.; Gogas, H.; Papadopoulos, S.; Malamou-Mitsi, V.; Scopa, C.D.; Markaki, S.; Karagianni, E.; Kyriakou, V.; Margariti, A.; et al. Evaluation of the prognostic value of HER-2 and VEGF in breast cancer patients participating in a randomized study with dose-dense sequential adjuvant chemotherapy. Breast Cancer Res. Treat. 2006, 96, 251-261.
93. Ludovini, V.; Sidoni, A.; Pistola, L.; Bellezza, G.; de Angelis, V.; Gori, S.; Mosconi, A.M.; Bisagni, G.; Cherubini, R.; Bian, A.R.; et al. Evaluation of the prognostic role of vascular endothelial growth factor and microvessel density in stages I and II breast cancer patients. Breast Cancer Res. Treat. 2003, 81, 159-168.
94. MacConmara, M.; O'Hanlon, D.M.; Kiely, M.J.; Connolly, Y.; Jeffers, M.; Keane, F.B. An evaluation of the prognostic significance of vascular endothelial growth factor in node positive primary breast carcinoma. Int. J. Oncol. 2002, 20, 717-721.
95. Schneider, B.P.; Wang, M.; Radovich, M.; Sledge, G.W.; Badve, S.; Thor, A.; Flockhart, D.A.; Hancock, B.; Davidson, N.; Gralow, J.; et al. Association of vascular endothelial growth factor and vascular endothelial growth factor receptor-2 genetic polymorphisms with outcome in a trial of paclitaxel compared with paclitaxel plus bevacizumab in advanced breast cancer: ECOG 2100. J. Clin. Oncol. 2008, 26, 4672-4678.